Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Antibodies, Immunity, and COVID-19

Antibodies, Immunity, and COVID-19 Antibodies, Immunity, and COVID-19 Invited Commentary Invited Commentary Brad Spellberg, MD; Travis B. Nielsen, PhD; Arturo Casadevall, MD, PhD Widespread availability of commercial assays that detect anti– than 60%, and perhaps up to 80%, of the population may need severe acute respiratory syndrome coronavirus 2 (SARS- immunity for the viral replication rate to drop below 1, en- CoV-2) antibodies has enabled researchers to examine natu- abling a modest level of disease control. Such immunity may rally acquired immunity to coronavirus disease 2019 (COVID- be achieved via recovery of many individuals from wide- 19) at the population level. spread infection, or preferably via the availability of safe and Several studies have found effective vaccines. Related article that the SARS-CoV-2 sero- Unfortunately, history has shown that although herd im- prevalence (the percentage of the population with serum con- munity resulting from infection can curb pandemics, it does taining antibodies that recognize the virus) has remained be- not eradicate diseases. The historical precedent that most low 20% even in the most adversely affected areas globally, closely approximates, and was substantially worse than, the 1-3 such as Spain and Italy. In this issue of JAMA Internal Medi- current COVID-19 pandemic is the 1918 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Loading next page...
 
/lp/american-medical-association/antibodies-immunity-and-covid-19-nxmrOuduyi
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2020.7986
Publisher site
See Article on Publisher Site

Abstract

Antibodies, Immunity, and COVID-19 Invited Commentary Invited Commentary Brad Spellberg, MD; Travis B. Nielsen, PhD; Arturo Casadevall, MD, PhD Widespread availability of commercial assays that detect anti– than 60%, and perhaps up to 80%, of the population may need severe acute respiratory syndrome coronavirus 2 (SARS- immunity for the viral replication rate to drop below 1, en- CoV-2) antibodies has enabled researchers to examine natu- abling a modest level of disease control. Such immunity may rally acquired immunity to coronavirus disease 2019 (COVID- be achieved via recovery of many individuals from wide- 19) at the population level. spread infection, or preferably via the availability of safe and Several studies have found effective vaccines. Related article that the SARS-CoV-2 sero- Unfortunately, history has shown that although herd im- prevalence (the percentage of the population with serum con- munity resulting from infection can curb pandemics, it does taining antibodies that recognize the virus) has remained be- not eradicate diseases. The historical precedent that most low 20% even in the most adversely affected areas globally, closely approximates, and was substantially worse than, the 1-3 such as Spain and Italy. In this issue of JAMA Internal Medi- current COVID-19 pandemic is the 1918

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Apr 24, 2021

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month